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BACKGROUND: Preoperative chemoradiotherapy (CRT) improves the survival of patients with oesophageal cancer when compared
with surgery alone.
METHODS: We conducted a phase II, multicenter trial of FOLFOX-4 and cetuximab in patients with locally advanced oesophageal
cancer (LAEC) followed by daily radiotherapy (180cGy fractions to 5040cGy) with concurrent weekly cetuximab. Cytokines
levels potentially related to cetuximab efficacy were assessed using multiplex-bead assays and enzyme-linked immunosorbent assay
at baseline, at week 8 and at week 17. Primary end point was complete pathological response rate (pCR).
RESULTS: In all, 41 patients were enroled. Among 30 patients who underwent surgery, a pCR was observed in 8 patients corresponding
to a rate of 27%. The most frequent grade 3/4 toxicity was skin (30%) and neutropenia (30%). The 36-month survival rates were
85 and 52% in patients with pathological CR or PR vs 38 and 33% in patients with SD or PD.
CONCLUSIONS: Incorporating cetuximab into a preoperative regimen for LAEC is feasible; no correlation between cytokines changes
and patient outcome was observed. Positron emission tomography/computed tomography study even if influenced by the small
number of patients appears to be able to predict patients outcome both as early and late metabolic response.
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Oesophageal cancer outcome remains poor. Surgery is still the first
choice of treatment for fit patients with resectable disease, but the
5-year survival is only 20–25% because lymphatic and haemato-
genous dissemination occurs early (Rice et al, 2009). Several
studies suggest that preoperative chemoradiation may improve
long-term outcome of resected patients when compared with
surgery alone. A recent meta-analysis examined 10 randomised
studies comparing trimodality therapy with surgery alone. Overall
results showed a statistically significant relative reduction in
mortality for patients receiving trimodality therapy with a hazard
ratio of 0.81 (Lv et al, 2009).
Optimisation of chemoradiotherapy (CRT) using targeted
therapies is a major goal of current research by increasing the
rate of pathological complete response (pCR) and consequently
overall survival (OS; Berger et al, 2005). Epidermal growth factor
receptors (EGFR) expression in oesophageal cancer ranges from
30 to 70%, and it has been shown to be a poor prognostic factor
(Ciardiello and Tortora, 2008). Monoclonal antibodies targeting
EGFR are being extensively evaluated in several cancer types
including oesophageal cancer. Data from phase III trials have
demonstrated an OS benefit with the addition of cetuximab to
radiation in head and neck cancer patients (Bonner et al, 2010).
Only one study incorporating cetuximab with CRT (carboplatin,
paclitaxel, and 50.4Gy of concurrent radiotherapy (RT)) has
recently been reported in oesophageal cancer. Patients achieved
an endoscopic complete response rate of 67% and, in those that
underwent surgery, 43% were found to have a pCR (Sgroi et al,
2008). Furthermore, oxaliplatin is active and less toxic than
cisplatin when administered in combination with 5-fluorouracil
(5-FU) and RT in patients with locally advanced oesophageal
cancer (LAEC), giving a 38% of pCR (Benjamini and Hochberg,
1995; Safran et al, 2008). Several studies conducted in colorectal
cancer have shown the feasibility of the combination of FOLFOX-4
and cetuximab (Tabernero et al, 2007; Bokemeyer et al, 2009).
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sOn the basis of these results, we designed a phase II multicenter
trial to assess the role of cetuximab as preoperative treatment
of LAEC. The potential toxicity from cetuximab concurrent with
chemotherapy and RT was poorly known at the time of study
design; therefore, we did not use a concurrent chemoradiation
regimen with cetuximab, but we decided to use an induction
chemotherapy treatment with FOLFOX-4 and cetuximab to reduce
the risk of distant metastases followed by RT and cetuximab. We
also evaluated, the early and late metabolic response as assessed by
18FDG-positron emission tomography (PET) and its correlation
with objective response to treatment. Moreover, we performed
explorative analyses of a pattern of cytokines and growth factors in
the serum of patient before and during therapy to evaluate their
potential value as predictive biomarkers for treatment outcome.
MATERIALS AND METHODS
Patient selection
Patients 18 years of age or older with locally advanced (T3–4,
N0 or any T, Nþ) and biopsy-confirmed adenocarcinoma or
squamous cell carcinoma of the oesophagus were enroled. Other
eligibility criteria included Eastern Cooperative Oncology Group
performance status of 0–2, no significant concomitant comorbid-
ities; adequate organ function (absolute neutrophil count X1500
cells0ml
 1, platelet count 4100000ml
 1, estimated creatinine
clearance 460mlmin
 1, normal bilirubin, aspartate aminotrans-
ferase and alanine aminotransferase o1.5  the institutional
upper limit of normal (ULN), and alkaline phosphatase o2.5 
ULN. Written informed consent was obtained from all patients.
Pre-treatment evaluation and treatment plan
Pre-treatment work-up included spiral computed tomography
(CT) scans of chest and abdomen and oesophageal ultrasound
endoscopic (EUS). To evaluate the correlation between metabolic
response to study treatment and pathological response, on July
2008 we emended the study introducing 18 FDG-PET scan.
A subset of patients was assessed by PET at the following time
points: 0 (baseline), 14 days, and at week 17 (at the end of RT and
before surgery). Patients were assigned to a preoperative clinical
stage according to the 2002 TNM System of the American Joint
Committee on Cancer. Chemotherapy consisted of oxaliplatin,
85mgm
 2 on day 1, folinic acid 200mgm
 2 as a 2h infusion on
days 1 and 2, and 5-FU, 400mgm
 2 bolus on days 1 and 2 followed
by 5-FU 600mgm
 2, a 22h continuous infusion on day 1 and 2;
cycles were administered every 2 weeks. Patients received
cetuximab i.v. at a starting dose of 400mgm
 2 followed by a
weekly infusion at a maintenance dose of 250mgm
 2. The
association of FOLFOX-4 and cetuximab was given for 8 weeks
before RT. Radiation therapy was delivered using 6–20MV X-ray
of a linear accelerator. The clinical target volume contained the
gross tumour with craniocaudal margins of at least 2cm and
transversal margins of 1cm; the target volume was identified based
on abnormalities observed in the oesophagus, proximal stomach
and regional lymph nodes on a pre-treatment diagnostic CT scan,
barium swallow and endoscopy. The dose to the spinal cord was
limited to 40Gy in all cases. A four-field conformal beam
arrangement consisting of opposed anterior and posterior and
lateral fields typically used. A dose of 1.8Gy was delivered daily
five times for 6 weeks up to a total dose of 50.4Gy.
The time frame between the end of chemotherapy and the
beginning of RT was 1 week.
Cetuximab was continued weekly during RT and for further
4 weeks during restaging.
Toxicity was assessed using the National Cancer Institute
Common Toxicity Criteria, version 2.0. Treatment delays and
dose modifications were based on the worst adverse effects
observed according to previous studies (Bokemeyer et al, 2009;
Bonner et al, 2010). This trial was approved by the Ethics
Committee of all participating institutions and was conducted in
accordance with Declaration of Helsinki, Good Clinical Practices,
local and legal requirements.
Surgery
Surgery was planned at 4 weeks after completion of restaging.
Thoracic oesophageal cancers were treated with laparotomy,
thoracotomy and cervicotomy followed by total oesophagectomy,
lymphadenectomy and gastroesophageal anastomosis in the left
neck. In abdominal oesophageal cancers, after gastric mobilisation
by laparotomy, oesophagectomy was performed by right thor-
acotomy and mediastinal oesophagogastro anastomosis. A radical
resection (R0, according to the criteria of the Union Internacional
Contra la Cancrum) was defined as the removal of all macroscopic
tumoural tissue, no evidence of distant metastases, the absence of
microscopic residual tumour, free resection margins and lympha-
denectomy extended beyond the involved nodes at post-operative
pathological examination. A resection was judged as non-radical
when microscopic (R1) or macroscopic (R2) residual tumour
was found.
Response assessment
Tumour response to treatment was assessed with CT scan, EUS
and PET scanning after CT and RT. Systematic biopsies were
required in all patients. A complete clinical response (cCR) was
defined as an absence of carcinoma cells in the endoscopic biopsy
and cytology specimens accompanying the disappearance
of radiographic evidence of disease. A clinical partial response
(cPR) was defined as a 450% regression in the volume of
radiological visible tumour. Progression corresponded to either
enlargement or appearance of new locoregional or distant disease.
After resection, the specimens were fixed with formaldehyde and
the complete tumour was embedded completely in paraffin blocks
and investigated histologically. The number of paraffin blocks
necessary differed with regard to the tumour size. The number of
histopathological sections differed regarding the size of the
specimen. The tissue was paraffin-embedded and serial sections
of each block were cut (5mm) and stained with hematoxylin and
eosin and periodic acid-Schiff. All specimens were classified
according to the criteria of Mandard using a tumour regression
grade (TRG). The TRG is based on the growth of residual tumour
into the areas of adjacent fibrosis. A resection specimen with no
residual tumour (complete response) is scored as TRG 1; the
presence of rare residual cancer cells scattered through fibrosis is
scored as TRG 2; an increased number of residual cancer cells but
where fibrosis still predominates is scored as TRG 3; residual
cancer outgrowing fibrosis is scored as TRG 4; and absence of
regressive changes is scored as TRG 5. For the study end points,
the histopathological response was divided into three groups:
group 1 consisted of patients with TRG 1 (pCR), group 2 included
patients with TRG 2, TRG 3 or TRG 4 (pPR), and group 3 consisted
of TRG 5 (stable disease).
Plasma collection and analyses
Plasma samples (2.5ml) were prepared from venous blood samples
collected at baseline (pre-treatment on day 1), week 8 (after
chemotherapy and before RT) and week 17 (after RT and before
surgery), frozen and stored at  801C until analysis. In all,
33 molecules including growth factors, chemokines, haemopoietins
were analysed by using enzyme-linked immunosorbent assay kits
from R&D Systems (Minneapolis, MN, USA) and luminex analysis
with multiplex beads suspension array plates (Invitrogen,
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sCarlsbad, CA, USA). Each sample was analysed in duplicate (the
complete list of assessed proteins is reported in Supplementary
Material Table 1).
Data collection and statistical analysis
Data were prospectively collected on forms to be filled out by the
investigators at inclusion, after completion of the treatment
sequence and at regular follow-up intervals. The primary end
point of the study was pCR rate, the secondary end points were
resection rate, overall survival and safety.
A two-stage Simon’s mini-max design was adopted. On the
basis of an a level of 5% and a power of 80% ‘for p0¼10% and
p1¼25%’, 18 subjects have to be enroled at the first step of the
study. In case of 2 or more with a pCR, the study would be
continued until the enrolment of final sample size. Survival curves
were constructed using the method of Kaplan and Meier (1958).
Analysis of metabolic response by PET and comparison
with histological response
To define the metabolic response, we applied three different
cutoffs: SUV reduction of 25, 35, or 50% compared with
baseline values. Therefore, patients were considered as metabolic
responders when they achieved a SUV reduction of at least 25,
35 or 50%, and as non-responders when they did not achieve a
reduction of at least 25, 35 or 50% of baseline SUV values
(Ott et al, 2006).
On the basis of histological specimen results, patients were
divided into histological responders (complete response/partial
response) or histological non-responders (all other patients
included those who did not undergo surgery because of tumour
progression).
Analysis of cytokines
Using Wilcoxon’s tests, we assessed which cytokines significantly
changed between different time points, specifically from baseline
to intermediate and from baseline to post treatment. Given the
large number of comparisons, we adjusted for multiple testing
using the false discovery rate methods, which is a standard
multiple test adjustment procedure (Storey, 2003). Specifically, we
apply the fdrtool method to map each P-value to a q-value, which
can be interpreted as the probability that the given factor is a false
discovery (Strimmer, 2000; Storey, 2003). We identified as
significant any factor with qo0.05.
Description of patterns of cytokines levels at baseline and during
treatment according to objective response (responders vs non-
responders) was essentially descriptive, and no formal statistical
tests were performed.
RESULTS
Patients characteristics
In all, 41 eligible patients with histological verified oesophageal
carcinoma were enroled between December 2006 and July 2009.
Figure 1 shows the trial profile. Baseline characteristics of the
study population are listed in Table 1.
Response to chemoradiation therapy
After four cycles, dysphagia relief was observed in 94% of 35
symptomatic patients. We excluded one patient from clinical
response evaluation because of early death for progression of the
disease during induction treatment. Among the 40 evaluable
patients, 6 had a cCR and 13 had a cPR, for an overall clinical
response rate of 47.5%. A total of 12 patients were classified as
stable (SD). A tumour progression (PD) was observed in nine
cases: six patients experienced distant metastases only, one patient
a locoregional failure only and two patients both local and distant
relapse.
Surgery
In all, 31 of the 40 patients were considered eligible for surgery, but
one refused surgery although in cCR. Therefore, 30/40 patients
underwent surgery and in 24/30 the resection was judged as
Untreated patients with histologically proven
locally advanced (T3–4/N0 or any T/N1)
epidermoid or adenocarcinoma of esophagus
(main inclusion criteria)
Folfox-4 + cetuximab
for 8 weeks
RT (50 Gy) + cetuximab
for 6 weeks
Cetuximab monotherapy
until surgery
Completed CRT
patients N=40 (97.5%)
After 4 weeks Restaging
Surgery Underwent surgery
patients N=30 (73%)
Progressed patients
N =9 (22.5%)
Died during CRT
patients N =1 (2.5%)
Enrolled patients
N=41 (100%)
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Figure 1 Trial design and profile.
Table 1 Patient characteristics
No. of patients¼41 (100%)
Age
Median/range 54/39–75
Sex
Male/female 30/11 (30/27)
Performance status
0/1 35/6 (85/15)
Dysphagia
Absent/moderate 7/8 (17/19)
Severe 26 (63)
Tumor location
Upper third 4 (10)
Middle third 17 (41)
Lower third 20 (49)
Histology
Adenocarcinoma 13 (32)
Squamous cell carcinoma 28 (68)
EUS T stage
a
2 11 (27)
3 25 (62)
4 3 (7)
EUS N stage
a
0 5 (12)
1/M1a 30/4 (73/10)
Abbreviation: EUS¼oesophageal ultrasound endoscopic.
aA total of 39/41 patients.
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scurative with no residual disease (R0 resection rate of 80%).
Six patients had microscopic residuals involving the resection
margins and precluding a radical tumour resection. Two patients
died after surgery with an operative mortality rate of 6%.
We observed three anastomotic stenoses that needed at least one
endoscopic dilatation.
A pCR (TRG1) was observed in eight patients corresponding to
a rate of 20%, whereas a pPR (TRG 2, 3 and 4) was recorded in
12 patients (30%) with an overall pathological response rate of
50%. Among those patients who underwent to surgery, the pCR
rate was 27%. Noteworthy, all pCR were observed in squamous cell
carcinoma. Table 2 shows the treatment efficacy according to the
intention to treat and in resected population.
Survival
All 41 patients were included in survival analysis according to the
intention to treat. At the end of the study, 21 patients had
died. The median and mean overall survival time was 17.3 and
16 months, respectively. The 12, 24 and 36 months overall survival
rates were: 67, 42, and 42%, respectively (Figure 2). The difference
in survival probability between inoperable and operable patients
was significant. In fact, the 12, 24 and 36 months survival
rates were 27.3, 18.2, and 18.2% in 11 non-resected patients, and
82.6, 51.1, and 51.1% in 30 resected patients, respectively
(HR¼3.81; 95% CI: 2.22–22.9; P¼0.0009). The 36-month
survival rates were 85 and 52% in patients with pathological CR
or PR vs 38 and 33% in patients without pathological downstaging
(SD or PD).
No differences in survival were detected among different
histological type. In particular, the 3-years survival was 57%
for squamous histology vs 41% for adenocarcinoma. P-value at
univariate analysis was 0.5729 with HR (95% CI) 0.72 (0.21–2.34)
and P-value at multivariate analysis of 0.3761 with HR (95% CI) of
3.65 (0.20–64.46).
Treatment-related toxicity
Treatment-related toxicity is summarised in Table 3. In all, 40
patients completed the preoperative treatment: one patient died
due to rapid progression of disease after two courses of
chemotherapy. A total of 162 courses of FOLFOX-4 were
administered and CT was delayed or modified in 2.9% of patients.
A total of 718 courses of cetuximab were administered with a
cetuximab delay or modification in 1.7% of patients. Radiotherapy
was delayed or modified in 2.7% of patients. The most common
grade 3 to 4 haematological and non-haematological toxicities
were skin 30% and neutropenia 30%. Oesophagitis was mainly
G1/G2 (77%); a G1/G2 neurotoxicity, was recorded in 47% of
patients. One patient experienced a serious cervical anastomotic
leak with severe mediastinitis and died at 2 months after the
operation; one patient died for septic shock.
18FDG-PET
Among 41 patients enroled in this study, 11 were excluded from
PET evaluation because of PET baseline assessment was not
performed. Therefore, 30 resulted potentially evaluable for
analysis. In all, 18 out of 30 patients underwent to 2 weeks
evaluation after starting treatment and 26 patients to PET scan as
planned at the end of treatment.
In 18 patients eligible for the analysis of predictive role of early
metabolic response, the mean baseline SUV was 12.89 (s.d.±5.66).
The mean 2 weeks SUV was 7.45 (s.d.±2.84). The mean percentage
reduction from baseline was 37.8% (s.d.±19.5%; P-value¼0.0009,
Wilcoxon rank sum test).
In 26 patients eligible for analysis of predictive role of post-
treatment metabolic response, the baseline SUV reported a mean
of 12.60% (s.d.±4.89). The mean SUV at the end of treatment was
3.80% (s.d.±3.88), with a mean percentage reduction of 63.0%
(s.d.±42.8; Po0.001, Wilcoxon rank sum test).
Evaluation of potential biomarkers in the plasma
In all, 33 different proteins plasma levels were measured in 28
patients at baseline, at intermediate (week 8) and post-treatment
evaluation (week 17).
Table 4 describes, for each cytokine analysed, median baseline
values and median changes from baseline, week 8 and at week 17.
At intermediate and post-treatment evaluation, levels of several
cytokines were significantly different even after multiple compar-
ison correction, with significance defined by local false discovery
rate qo0.05, upper limit of normal. However when these
variations were evaluated according to response to treatment,
there was no major difference between cytokine variation levels
among responding and non-responding patients (Supplementary
Material Figures 1 and 2).
Table 2 Treatment activity
Number of
patients
Intention to
treat
patients¼41
(100%)
Patients undergoing
surgery
patients¼30
(100%)
Path CR 8 (19.5) (26.6)
Path PR 12 (29.6) (40)
Overall path RR 20 (48.7) (66.6)
R0 surgery 24 (58.5) (80.0)
Abbreviations: path CR¼pathological response rate; path PR¼pathological partial
response; RR¼response rate.
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Figure 2 Kaplan–Meier plots of overall survival. The median and mean
overall survival time was 17.3 and 16 months, respectively. The 12, 24 and
36 months overall survival rates were: 67, 42, and 42%, respectively.
Table 3 Treatment-related toxicity
Toxicity G0 (%) G1 (%) G2 (%) G3 (%) G4 (%)
Skin 7 13 50 30 0
Neutropenia 40 23 7 20 10
Anemia 83 12 5 0 0
Esophagitis 23 45 32 0 0
Nausea/vomiting 53 35 12 0 0
Diarrhea 85 10 5 0 0
Stomatitis 75 20 5 0 0
Neurotoxicity 53 45 2 0 0
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sDISCUSSION
The role of trimodality therapy of LAEC remains debated, but
several data suggest a better outcome for preoperative CRT-treated
patients. Despite this strategy, most of the patients develop distant
metastases and die of their disease. At this time, pCR appears as an
early marker of the efficacy of CRT and patients who achieve a
pCR have an improved survival as shown in literature-based
meta-analyses and phase II and phase III studies (Janmaat et al,
2006; Safran et al, 2008; Al-Batran et al, 2009). Also our previous
experiences confirmed that complete pathological responder
patients had a significant longer survival probability compared
with patients with partial response or stable disease after
preoperative CRT (De Vita et al, 2002; Orditura et al, 2010).
To improve the efficacy of systemic treatments in combination
with RT, a series of clinical studies are currently evaluating the
addiction of molecular targeted agents with the aim of increasing
the pCR; therefore, the assessment of pCR was the primary end
point of this study. In this study, we report that a combined
treatment consisting of 2 months of cetuximab plus FOLFOX-4
followed by 6 weekly radiation therapy plus cetuximab achieved a
pCR rate of 27% in resected patients. This rate of pCR could
appear lower if compared with a previous study with concurrent
cetuximab, chemotherapy and RT (Safran et al, 2008). Never-
theless, we must underline the different study design with the
choice, in the present trial, of a sequential rather than concurrent
CRT approach. In fact, this trial was planned when few data were
available about toxicity of concurrent RT, chemotherapy and
cetuximab; this was also the reason for giving induction therapy to
handle the high risk of distant metastases observed in LAEC.
However, it is important to emphasise that pCRs vary in different
studies from 17 to 51% with most large randomised trials
demonstrating rates of pCR ranging from 10 to 30% (Apinop
et al, 1994; Le Prise et al, 1994; Walsh et al, 1996; Bosset et al, 1997;
Urba et al, 2001; Burmeister et al, 2005). The current pCR rate of
27% is consistent with the results of these trials. The survival
observed in our study appears consistent with that observed in
most large randomised trials. The median OS was 17.3 months
with a 3-year OS of 42%, whereas the median OS in large
randomised trials ranges from 10 to 19 months with a 3-year
OS rate of 19–39% (Apinop et al, 1994; Le Prise et al, 1994;
Walsh et al, 1996; Bosset et al, 1997; Urba et al, 2001; Burmeister
et al, 2005). Furthermore, the present data suggest a significant
survival benefit for patients experiencing a pCR, who obtained a
3-year OS rate of 85%.
One of the most important factors conditioning survival
of patients undergoing oesophagectomy is an R0 resection. We
obtained an R0 resection in 80% of resected patients, and this R0
resection rate compares favourably with those reported in the
literature, which are typically above 80% (Hofstetter et al, 2002;
Mariette et al, 2003).
This regimen was generally well tolerated. The rates and types of
adverse events in our patients were consistent with those expected
from the individual agents, with the exception of skin reactions
due to cetuximab; 26% of patients experienced a grade 3–4
dermatological toxicity but there was not an increase in
oesophagitis or other radiation-enhanced toxicity.
The PET evaluation was limited by the small number of patients.
However, all the three cutoffs used (25, 35 and 50%) demonstrated,
in a descriptive manner, that SUV reduction, between scans
carried out at the end of treatment and the one at baseline,
correlates with the response to the treatment. These data suggest
that the metabolic response can be used as a parameter of patients
outcome. Therefore, PET assessment of early metabolic response
could be incorporated in future clinical trials of multimodality
treatment for LAEC.
Finally, the explorative plasma analysis showed that protein
modifications recorded at different time points respect to the basal
concentrations, are not correlated with the efficacy of treatment,
even for those proteins that shown a significant change (decrease
or increase) in the whole population. Changes in these proteins
are not strongly related to modification in tumour burden. It may
be that the protein changes observed could be related to the
general clinical status, to the local systemic inflammatory
modifications secondary to the tumour, and/or to the body
response to a combined approach such as CT and RT administered
in combination with a monoclonal antibody.
In conclusion, this study shows that the combination
of FOLFOX-4 and cetuximab followed by cetuximab and
concurrent radiation is an active and safe preoperative regimen
for LAEC.
Table 4 Cytokine value at baseline, at week 7 and week 17
Intermediate Post-treatment
Cytokine
Baseline
median % Baseline
a P % Baseline
a P
Growth factors
VEGF 178.1 NA NA 120 0.5891
HGF 257.5 91 0.1479 62 0.0493
FGFb 8.9 89 0.0448 80 o0.0001
b
PlGF 38.8 108 0.927 91 0.915
Epiregulin 1.0 90 0.4807 78 0.6824
TGFa 39.8 98 0.9933 108 0.3316
EGF 29.6 53 0.3408 69 0.444
Chemokines
Eotaxin 56.0 81 0.4527 33 0.0001
b
IL 8 3.5 92 0.4282 72 0.1772
IP 10 8.0 148 0.0029
b 151 0.0084
b
MCP 1 175.5 76 0.3629 67 0.0652
b
MIG 15.2 88 0.3598 61 0.0159
b
MIP-1A 39.7 58 o0.0001
b 37 o0.0001
b
MIP-1B 47.2 58 0.0112
b 39 o0.0001
b
RANTES 5696.9 122 0.0724 251 0.045
Haemopoietins
G-CSF 59.1 80 0.0014
b 81 0.0159
b
GM-CSF 19.3 100 0.0135
b 103 o0.0001
b
IL 2 1.4 99 0.2637 82 0.0201
b
IL 2R 194.2 85 0.467 84 0.129
IL 4 27.5 49 0.0003
b 43 o0.0001
b
IL 5 14.1 41.3 0.2881 12 o0.0001
b
IL 6 2.3 136 0.0164
b 142 0.0003
b
IL 7 11.0 142 0.0001
b 175 o0.0001
b
IL 13 7.2 100 0.5558 100 1
IL 15 13.3 84 0.0049
b 63 o0.0001
b
Other molecules
IFNa 20.7 88 0.3498 67 o0.0001
b
IFNg 52.6 52 o0.0001
b 35 o0.0001
b
TNF-A 7.3 49 o0.0001
b 48 o0.0001
b
IL 1b 13.3 69 0.0008
b 57 o0.0001
b
IL 1Ra 373.1 46 0.0002
b 52 0.0002
b
IL 10 1.8 183 0.001
b 315 o0.0001
b
IL 12 185.1 42 o0.0001
b 21 o0.0001
b
IL 17 13.6 82 0.1247 74 0.0044
b
Abbreviations: EGF¼epidermal growth factor; FGF¼fibroblast growth factor;
G-CSF¼granulocyte colony-stimulating factor; GM-CSF¼granulocyte–macrophage
colony-stimulating factor; HGF¼hepatocyte growth factor; IL¼interleukin;
INF¼interferon; IP¼inducible protein; MCP¼monocyte chemoattractant protein;
MIG¼monokine induced by gamma interferon; MIP¼macrophage inflammatory
proteins; NA¼not available; PlGF¼placenta growth factor; RANTES¼regulated on
activation normal T cell expressed and secreted; TGF¼transforming growth factor;
TNF¼tumour necrosis factor; VEGF¼vascular endothelial growth factor.
aThe
median of the ratios of cytokine and angiogenic factor concentration at each time
point to baseline concentration expressed as a percentage.
bSignificant after
correction for multiple comparisons (see text).
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